* on regular asa treatment for pre-eclampsia prevention * on long-term non-steroidal anti-inflammatory medication * bleeding disorders, mainly haemophilia, hypoprothrombinaemia orvon willebrand's disease * history of hypersensitivity to asa or to any of the excipients of the investigational product. * history of peptic ulceration, including active, chronic or recurrent gastroduodenal ulcer; recurrent gastric discomfort history of gastric bleeding or perforation after treatment with aspirin or other non-steroidal anti-inflammatory drugs * inability to cooperate with the requirements of the study * severe covid-19 disease (with any of the following: respiratory rate \> 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). * treatment resistant hyperemesis gravidarum * hypersensitivity to nonsteroidal anti-inflammatory drugs or to tartrazine (cross-reaction) or to any of the excipients used in its composition. * asthma. * severe renal or hepatic insufficiency. * nasal polyps associated with asthma that are induced or exacerbated by aspirin. * severe covid-19 disease (with any of the following: respiratory rate \> 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). * treatment resistant hyperemesis gravidarum

* on regular asa treatment for pre-eclampsia prevention * on long-term non-steroidal anti-inflammatory medication * bleeding disorders, mainly haemophilia, hypoprothrombinaemia orvon willebrand's disease * history of hypersensitivity to asa or to any of the excipients of the investigational product. * history of peptic ulceration, including active, chronic or recurrent gastroduodenal ulcer; recurrent gastric discomfort history of gastric bleeding or perforation after treatment with aspirin or other non-steroidal anti-inflammatory drugs * inability to cooperate with the requirements of the study * severe covid-19 disease (with any of the following: respiratory rate \> 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). * treatment resistant hyperemesis gravidarum * hypersensitivity to nonsteroidal anti-inflammatory drugs or to tartrazine (cross-reaction) or to any of the excipients used in its composition. * asthma. * severe renal or hepatic insufficiency. * nasal polyps associated with asthma that are induced or exacerbated by aspirin. * severe covid-19 disease (with any of the following: respiratory rate \> 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). * treatment resistant hyperemesis gravidarum

on regular asa treatment for pre-eclampsia prevention on long-term non-steroidal anti-inflammatory medication bleeding disorders, mainly haemophilia, hypoprothrombinaemia orvon willebrand's disease history of hypersensitivity to asa or to any of the excipients of the investigational product. history of peptic ulceration, including active, chronic or recurrent gastroduodenal ulcer; recurrent gastric discomfort history of gastric bleeding or perforation after treatment with aspirin or other non-steroidal anti-inflammatory drugs inability to cooperate with the requirements of the study severe covid-19 disease (with any of the following: respiratory rate > 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). treatment resistant hyperemesis gravidarum hypersensitivity to nonsteroidal anti-inflammatory drugs or to tartrazine (cross-reaction) or to any of the excipients used in its composition. asthma. severe renal or hepatic insufficiency. nasal polyps associated with asthma that are induced or exacerbated by aspirin. severe covid-19 disease (with any of the following: respiratory rate > 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). treatment resistant hyperemesis gravidarum

on regular asa treatment for pre-eclampsia prevention on long-term non-steroidal anti-inflammatory medication bleeding disorders, mainly haemophilia, hypoprothrombinaemia orvon willebrand's disease history of hypersensitivity to asa or to any of the excipients of the investigational product. history of peptic ulceration, including active, chronic or recurrent gastroduodenal ulcer; recurrent gastric discomfort history of gastric bleeding or perforation after treatment with aspirin or other non-steroidal anti-inflammatory drugs inability to cooperate with the requirements of the study severe covid-19 disease (with any of the following: respiratory rate > 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). treatment resistant hyperemesis gravidarum hypersensitivity to nonsteroidal anti-inflammatory drugs or to tartrazine (cross-reaction) or to any of the excipients used in its composition. asthma. severe renal or hepatic insufficiency. nasal polyps associated with asthma that are induced or exacerbated by aspirin. severe covid-19 disease (with any of the following: respiratory rate > 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). treatment resistant hyperemesis gravidarum

- on regular asa administration - on long-term non-steroidal anti-inflammatory medication - bleeding disorders such as von willebrand's disease - history of peptic ulceration - history of hypersensitivity to asa - participation in another clinical trial - inability to cooperate with the requirements of the study - severe covid-19 disease (with any of the following: respiratory rate > 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). - treatment resistant hyperemesis gravidarum

- on regular asa administration - on long-term non-steroidal anti-inflammatory medication - bleeding disorders such as von willebrand's disease - history of peptic ulceration - history of hypersensitivity to asa - participation in another clinical trial - inability to cooperate with the requirements of the study - severe covid-19 disease (with any of the following: respiratory rate > 30 breaths/min; severe respiratory distress; spo2 ≤ 93% on room air; acute respiratory distress syndrome; sepsis with acute organ dysfunction). - treatment resistant hyperemesis gravidarum